Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 9/2004

01-05-2004 | Review Article

Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia

Authors: Pamela S. Davies, Dr Bradley S. Galer

Published in: Drugs | Issue 9/2004

Login to get access

Abstract

Postherpetic neuralgia (PHN) is a chronic pain syndrome that disproportionately affects the elderly; its incidence is anticipated to increase as the population ages. PHN presents as pain (continuous burning or intense paroxysmal), most often with tactile allodynia, which may be severe and disabling, resulting in poor quality of life and depression. Traditional treatments have included tricyclic antidepressants, anticonvulsants and opioids; however, adverse systemic effects associated with these agents have led to the development of a newer and potentially safer agent, the topical lidocaine patch 5% (Lidoderm®), a targeted peripheral analgesic.

This article reviews the clinical pharmacology of the lidocaine patch 5% for the treatment of PHN and summarises data from clinical trials of its safety, tolerability and efficacy. The Medline search terms ‘lidocaine’ and ‘patch’ were used to search for English-language articles on the pharmacokinetics of the lidocaine patch 5% and its clinical use for the treatment of PHN. Additional published studies not identified by the database search but performed by the authors or their colleagues were also included in the review.

The systemic absorption of lidocaine from the patch was minimal in healthy adults when four patches were applied for up to 24 hours/day, and lidocaine absorption was even lower among PHN patients than healthy adults at the currently recommended dose. Vehicle-controlled and open-label trials found the lidocaine patch 5%, either alone or in combination with other agents, to be effective in the treatment of PHN. Most adverse events were at patch application sites; no clinically significant systemic adverse effects were noted, including when used long term or in an elderly population.

In patients with PHN, the lidocaine patch 5% has demonstrated relief of pain and tactile allodynia with a minimal risk of systemic adverse effects or drug-drug interactions. Because of its proven efficacy and safety profile, the lidocaine patch 5% has been recommended as a first-line therapy for the treatment of the neuropathic pain of PHN.

Footnotes
1

The use of trade names is for product identification purposes only and does not imply endorsement.

 
Literature
  1. Watson CP. A new treatment for postherpetic neuralgia. N Engl J Med 2000 Nov 23; 343(21): 1563–5PubMedView Article
  2. Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995 Aug 7–21; 155(15): 1605–9PubMedView Article
  3. Gnann Jr JW, Whitley RJ. Clinical practice: herpes zoster. N Engl J Med 2002 Aug 1; 347(5): 340–6PubMedView Article
  4. Lee PJ, Annunziato P. Current management of herpes zoster. Infect Med 1998; 15: 709–13
  5. Choo PW, Galil K, Donahue JG, et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997 Jun 9; 157(11): 1217–24PubMedView Article
  6. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996 Jul 4; 335(1): 32–42PubMedView Article
  7. Schmader K. Postherpetic neuralgia in immunocompetent elderly people. Vaccine 1998 Nov; 16(18): 1768–70PubMedView Article
  8. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003 Apr 1; 36(7): 877–82PubMedView Article
  9. Rowbotham MC, Fields HL. Post-herpetic neuralgia: the relation of pain complaint, sensory disturbance, and skin temperature. Pain 1989 Nov; 39(2): 129–44PubMedView Article
  10. Nurmikko T, Wells C, Bowsher D. Sensory dysfunction in postherpetic neuralgia. In: Boivie J, Hansson P, Lindblom U, editors. Touch, temperature and pain in health and disease: mechanisms and assessments. Seattle (WA): IASP Press, 1994: 133–41
  11. Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982 Jun; 32(6): 671–3PubMedView Article
  12. Kishore-Kumar R, Max MB, Schafer SC, et al. Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990 Mar; 47(3): 305–12PubMedView Article
  13. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998 Dec; 280(21): 1837–42PubMedView Article
  14. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998 Jun; 50(6): 1837–41PubMedView Article
  15. Rowbotham MC, Twilling L, Davies PS, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003 Mar 27; 348(13): 1223–32PubMedView Article
  16. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis. I: psychotropic drugs. J Am Geriatr Soc 1999 Jan; 47(1): 30–9
  17. Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989 Aug; 21 (2 Pt 1): 265–70PubMedView Article
  18. Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993 May–Jun; 15(3): 510–26PubMed
  19. Litman SJ, Vitkun SA, Poppers PJ. Use of EMLA cream in the treatment of post-herpetic neuralgia. J Clin Anesth 1996 Feb; 8(1): 54–7PubMedView Article
  20. Collins PD. EMLA cream and herpetic neuralgia. Med J Aust 1991 Aug 5; 155(3): 206–7PubMed
  21. Wheeler JG. EMLA cream and herpetic neuralgia [letter]. Med J Aust 1991 Jun 3; 154(11): 781PubMed
  22. Stow PJ, Glynn CJ, Minor B. EMLA cream in the treatment of post-herpetic neuralgia: efficacy and pharmacokinetic profile. Pain 1989 Dec; 39(3): 301–5PubMedView Article
  23. Attal N, Brasseur L, Chauvin M, et al. Effects of single and repeated applications of a eutectic mixture of local anaesthetics (EMLA) cream on spontaneous and evoked pain in postherpetic neuralgia. Pain 1999 May; 81(1–2): 203–9PubMedView Article
  24. Chabal C, Russell LC, Burchiel KJ. The effect of intravenous lidocaine, tocainide, and mexiletine on spontaneously active fibers originating in rat sciatic neuromas. Pain 1989 Sep; 38(3): 333–8PubMedView Article
  25. Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 1993 May; 13(5): 1976–92PubMed
  26. Baron R. Peripheral neuropathic pain: from mechanisms to symptoms. Clin J Pain 2000 Jun; 16 (2 Suppl.): S12–20PubMedView Article
  27. Kennedy PG. Varicella-zoster virus latency in human ganglia. Rev Med Virol 2002 Sep–Oct; 12(5): 327–34PubMedView Article
  28. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995 Feb; 37(2): 246–53PubMedView Article
  29. Lidoderm® (lidocaine patch 5%) prescribing information. Chadds Ford (PA): Endo Pharmaceuticals Inc., 2000
  30. Comer AM, Lamb HM. Lidocaine patch 5%. Drugs 2000 Feb; 59(2): 245–9PubMedView Article
  31. Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002 May; 91(5): 1343–50PubMedView Article
  32. Galer BS. Lidocaine patch 5%: viewpoints. Drugs 2000 Feb; 59(2): 250–1View Article
  33. Galer BS. Effectiveness and safety of lidocaine patch 5%. J Fam Pract 2002 Oct; 51(10): 867–8PubMed
  34. Argoff CE. Lidocaine patch 5% and the management of chronic pain [letter]. South Med J 2002 Jul; 95(7): 781PubMedView Article
  35. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002 Feb; 36(2): 236–40PubMedView Article
  36. Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm 2002 Nov 15; 59(22): 2215–20PubMed
  37. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996 Apr; 65(1): 39–44PubMedView Article
  38. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999 Apr; 80(3): 533–8PubMedView Article
  39. Galer BS, Jensen MP, Ma T, et al. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale. Clin J Pain 2002 Sep—Oct; 18(5): 297–301PubMedView Article
  40. Rowbotham MC, Davies PS, Galer BS. Multicenter, double-blind, vehicle-controlled trial of long-term use of lidocaine patches for postherpetic neuralgia [abstract no. 184]. In: Abstracts of the 8th World Congress of the International Association for the Study of Pain; 1996 Aug 17–22; Vancouver (BC). Proceedings of the 8th World Congress on Pain. San Diego (CA): IASP Press, 1997: 274
  41. Katz NP, Gammaitoni AR, Davis MW, et al. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial: the Lidoderm Patch Study Group. Pain Med 2002; 3(4): 324–32PubMedView Article
  42. Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003 Mar 10; 163(5): 628PubMedView Article
  43. Benowitz NL, Meister W. Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet 1978 May–Jun; 3(3): 177–201PubMedView Article
  44. Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997 Feb; 48(2): 332–8PubMedView Article
  45. McAlister FA, Straus SE, Guyatt GH, et al. Users’ guides to the medical literature. Integrating research evidence with the care of the individual patient: Evidence-Based Medicine Working Group. JAMA 2000 Jun 7; 283(21): 2829–36
  46. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151–8PubMedView Article
  47. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002 Oct; 59(7): 1015–21PubMedView Article
  48. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001 Nov; 94(2): 215–24PubMedView Article
  49. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999 Dec; 83(3): 389–400PubMedView Article
  50. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60(11): 1524–34PubMedView Article
  51. Gimbel J, Hale M, Linn R, et al. Lidocaine patch 5% in patients with acute/subacute and chronic low back pain: impact on pain intensity, pain relief, and pain interference with quality of life [abstract no. 878]. J Pain 2003; 4 Suppl. 1: 71
  52. Gammaitoni AR, Galer BS, Burch F, et al. Effectiveness and safety of the lidocaine patch 5% as monotherapy in patients with pain from osteoarthritis of the knee [abstract no. 906]. J Pain 2003; 4 Suppl. 1: 78
Metadata
Title
Review of Lidocaine Patch 5% Studies in the Treatment of Postherpetic Neuralgia
Authors
Pamela S. Davies
Dr Bradley S. Galer
Publication date
01-05-2004
Publisher
Springer International Publishing
Published in
Drugs / Issue 9/2004
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200464090-00002

Other articles of this Issue 9/2004

Drugs 9/2004 Go to the issue

Aids Drug Profile

Micafungin

Review Article

Antifungals in Systemic Neonatal Candidiasis

Leading Article

Glycopeptide Antibiotics

Adis Drug Profile

Micafungin

Adis Drug Profile

Lanthanum Carbonate

Adis Drug Evaluation

Irbesartan